Cempra (CEMP) PT Slashed to $2 at Baird Amid CRL

Morgan Stanley Upgrades Cempra, Inc. (CEMP) to Equalweight

Morgan Stanley upgraded Cempra, Inc. (NASDAQ: CEMP) from Underweight to Equalweight with a price target of $3.00 (from $5.00) after the FDA issued a CRL on Solithera and the related 57.6% sell-off.

For an analyst ratings summary and ratings history on Cempra, Inc.... More

WBB Securities Downgrades Cempra, Inc. (CEMP) to Hold

WBB Securities downgraded Cempra, Inc. (NASDAQ: CEMP) from Strong Buy to Hold with a price target of $4.00 (from $40.00) following today's CRL.

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Ladenburg Thalmann Downgrades Cempra, Inc. (CEMP) to Neutral

Ladenburg Thalmann downgraded Cempra, Inc. (NASDAQ: CEMP) from Buy to Neutral.

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Shares of Cempra, Inc. closed at $6.10 yesterday.

Meaningful Commercial role for Cempra's (CEMP) Solithera 'Unlikely' - Needham & Company

Needham & Company analyst Alan Carr reiterated a Hold rating on Cempra, Inc. (NASDAQ: CEMP) after the FDA issued a CRL on Solithera.

Carr commented, "The agency reportedly informed company that safety profile of Solithera has not been adequately characterized and a larger safety... More

Wall St. edges lower as bank shares fall

NEW YORK (Reuters) - Wall Street closed slightly lower on Thursday as bank shares declined in quiet holiday trading as traders looked to position for the new year.

The Dow Jones Industrial Average fell 13.14 points, or 0.07 percent, to 19,820.54, the S&P 500 lost 0.56 points, or 0.02 percent, to 2,249.36 and... More

Cempra (CEMP) Sinks 14% Following FDA CRL on Solithromycin

Cempra, Inc. (Nasdaq: CEMP) is down 13.9% in pre-open trade Thursday after the company announced that it has received a Complete Response Letter... More

Cempra (CEMP) Receives FDA CRL for Solithromycin NDAs

Cempra (Nasdaq: CEMP) announced that the company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) relating to the companys new drug applications (NDAs) for oral and intravenous solithromycin for the treatment of community-acquired bacterial pneumonia (CABP) in adults.

The CRL states that the FDA cannot approve the NDAs in their present form and notes that additional clinical safety information and the satisfactory resolution of manufacturing facility inspection deficiencies are required before the NDAs may be... More

Cempra (CEMP) January volatility above 200 into FDA PDUFA Date

Cempra (NASDAQ: CEMP) January call option implied volatility is at 201, February is at 154; compared to its 52-week range of 69 to 260 into a FDA PDUFA Date for Cempra Oral Solithromycin IV formulation on December 28, 2016.

Pre-Open Stock Movers 12/28: (LIVE) (GALE) (OCRX) Higher; (ANTH) (QCOM) Lower (more...)

Today's Pre-Open Stock Movers

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) 62.7% LOWER; announced the top line results of the SOLUTION clinical study in cystic fibrosis patients with exocrine pancreatic insufficiency (EPI). The study narrowly missed the CFA non-inferiority margin of the primary modified Intent to Treat (mITT) analysis; however, by additional pre-specified analyses of CFA (mITT-Baseline Observation Carried Forward and Per Protocol), Sollpura met the non-inferiority criterion. The study also confirmed that the ratio of the three enzymes in Sollpura demonstrated an appropriate response in the coefficient... More

Cempra (CEMP) Gains Ahead of Solithromycin PDUFA Dates

Cempra (NASDAQ: CEMP) is gaining 3.4% in pre-open trade Wednesday ahead of the PDUFA dates for solithromycin for the treatment of community-acquired bacterial pneumonia (CABP). The target date for the FDA to take action under the Prescription Drug User Fee Act (PDUFA) is December 27... More

After-Hours Movers 12/27: (CEMP) Higher; (ATHN) Lower

Today's After-Hours Movers

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) 66% LOWER; announced the top line results of the SOLUTION clinical study in cystic fibrosis patients with exocrine pancreatic insufficiency (EPI). The study narrowly missed the CFA non-inferiority margin of the primary... More